
|Articles|August 13, 2014
- Gastrointestinal Cancers (Issue 2)
- Volume 2
- Issue 1
An Analysis of Bevacizumab or Cetuximab for CRC
Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).
Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).
Read more about the treatment of CRC > >
Articles in this issue
over 11 years ago
The Importance of Testing for BRAF Status in CRC Patientsover 11 years ago
Proactive Management of Regorafenib-Associated AEsover 11 years ago
Survival Benefit Confirmed With Palliative Resection in mCRC




































